VOQUEZNA Data Sparks Interest: Recent chatter on X about Phathom Pharmaceuticals (PHAT) has centered on the newly published data from their Phase 3 pHalcon-NERD-301 study. Posts highlight that VOQUEZNA, their treatment for non-erosive reflux disease, showed significant improvement in nighttime GERD symptoms. Many are intrigued by the potential market impact of these results.
Upcoming Earnings in Focus: Discussion on X also revolves around Phathom’s upcoming Q3 2025 earnings report, set for release on October 30. Users are speculating on whether the positive clinical data and raised guidance earlier this year will reflect in strong financials. There’s a palpable anticipation for updates on VOQUEZNA’s commercial performance.
Note: This discussion summary was generated from an AI condensation of post data.
Phathom Pharmaceuticals Insider Trading Activity
Phathom Pharmaceuticals insiders have traded $PHAT stock on the open market 10 times in the past 6 months. Of those trades, 8 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PHAT stock by insiders over the last 6 months:
- JAMES N TOPPER has made 6 purchases buying 59,403 shares for an estimated $191,988 and 0 sales.
- ASIT PARIKH has made 2 purchases buying 10,000 shares for an estimated $24,984 and 0 sales.
- ROBERT CHARLES BREEDLOVE (Principal Accounting Officer) has made 0 purchases and 2 sales selling 2,153 shares for an estimated $19,725.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Phathom Pharmaceuticals Hedge Fund Activity
We have seen 59 institutional investors add shares of Phathom Pharmaceuticals stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 7,042,325 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $67,535,896
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 2,357,210 shares (+23.3%) to their portfolio in Q2 2025, for an estimated $22,605,643
- MILLENNIUM MANAGEMENT LLC added 1,727,134 shares (+330.0%) to their portfolio in Q2 2025, for an estimated $16,563,215
- TANG CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,508,000
- MORGAN STANLEY removed 976,104 shares (-86.3%) from their portfolio in Q2 2025, for an estimated $9,360,837
- CATALIO CAPITAL MANAGEMENT, LP added 672,290 shares (+inf%) to their portfolio in Q2 2025, for an estimated $6,447,261
- 683 CAPITAL MANAGEMENT, LLC added 660,000 shares (+45.7%) to their portfolio in Q2 2025, for an estimated $6,329,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Phathom Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $PHAT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 06/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/09/2025
- Needham issued a "Buy" rating on 06/06/2025
- Guggenheim issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for Phathom Pharmaceuticals, check out Quiver Quantitative's $PHAT forecast page.
Phathom Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $PHAT recently. We have seen 5 analysts offer price targets for $PHAT in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Chase Knickerbocker from Craig-Hallum set a target price of $17.0 on 06/09/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $20.0 on 06/09/2025
- Joseph Stringer from Needham set a target price of $28.0 on 06/06/2025
- Paul Choi from Goldman Sachs set a target price of $5.0 on 05/02/2025
- Yatin Suneja from Guggenheim set a target price of $12.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
